Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 | DelveInsight

The liquid biopsy in cancer diagnostics market is anticipated to experience growth due to factors such as the increasing occurrence of diverse cancers, rising interest in minimally invasive procedures, growing demand for precision medicine, and ongoing technical innovations in product development, among other contributing factors.

LAS VEGAS, Jan. 19, 2024 /PRNewswire/ -- DelveInsight's Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading liquid biopsy in cancer diagnostics companies' market shares, challenges, liquid biopsy in cancer diagnostics market drivers, barriers, trends, and key market liquid biopsy in cancer diagnostics companies in the market.

Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global liquid biopsy in cancer diagnostics market during the forecast period. 
• Notable liquid biopsy in cancer diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and several others, are currently operating in the liquid biopsy in cancer diagnostics market.
• In January 2024, PrognomiQ, a healthcare firm dedicated to leveraging multi-omics data to revolutionize the early identification, treatment choice, and monitoring of cancer and intricate diseases, revealed encouraging findings from the most extensive deep multi-omics investigation to date. The study, available online in medRxiv, concentrated on individuals with susceptibility to lung cancer and showcased the effectiveness of multi-omics in achieving both heightened sensitivity and specificity for the early detection of lung cancer in its initial stages.
• In January 2024, Aditxt, Inc., a firm committed to exploring, advancing, and implementing promising healthcare breakthroughs, declares the successful acquisition of MDNA Life Sciences Inc.'s exclusive platform for early disease and cancer detection. This strategic decision further underscores Pearsanta, Inc.'s commitment to improving patient outcomes by focusing on early disease detection and the effectiveness of precision diagnostics.
• In January 2024, PanGIA Biotech, a biotechnology firm headquartered in the United States, is on a mission to create scalable liquid biopsy technology with a global reach. The company has revealed that it is in the final stages of completing a three-year prospective multicenter clinical study focused on liquid biopsy for prostate cancer.
• In December 2023, Exai Bio revealed recent findings showcasing the capability of its innovative liquid biopsy platform, which combines RNA technology with artificial intelligence. The platform can identify breast cancer in its earliest phases and detect even the smallest tumors, such as ductal carcinoma in situ (DCIS), using a regular blood sample. In a fresh study focused on early detection and expanding on previous results, the sensitivity for stage I breast cancer reached 87%, and the sensitivity for tumors of size T1a-b (10 mm or smaller) was 81%, both with a specificity of 90%.

To read more about the latest highlights related to liquid biopsy in cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Liquid Biopsy in Cancer Diagnostics Market Report

Liquid Biopsy in Cancer Diagnostics Overview

Liquid biopsy is a revolutionary approach in cancer diagnostics that has emerged as a promising alternative to traditional tissue biopsies. Unlike conventional biopsies, which involve invasive procedures to extract tissue samples, liquid biopsy harnesses the power of a patient's blood or other bodily fluids to detect and analyze cancer-related genetic mutations, circulating tumor cells (CTCs), and cell-free DNA (cfDNA). This non-invasive technique offers a dynamic and real-time view of the tumor's genetic landscape, enabling oncologists to monitor disease progression, assess treatment response, and identify potential therapeutic targets with greater precision. 

Liquid biopsy has shown particular utility in cases where obtaining tissue samples is challenging or risky, such as in metastatic cancers or when the tumor location is inaccessible. The ability to obtain valuable genetic information from a simple blood draw represents a significant advancement in personalized medicine, allowing for more timely and tailored interventions in the evolving landscape of cancer care. As research in this field continues to expand, liquid biopsy holds immense promise for improving early detection, monitoring treatment efficacy, and guiding therapeutic decisions in the realm of cancer diagnostics.

Liquid Biopsy in Cancer Diagnostics Market Insights

Among all regions, North America is projected to hold a substantial portion of the market share within liquid biopsy for cancer diagnostics. This prominence is anticipated due to several factors such as the rising incidence of cancers, an amplified emphasis on oncology research, supportive governmental initiatives endorsing liquid biopsy exploration, and a favorable landscape for product innovation and introduction in the area. Within North America, the United States, specifically, contributed to 87% of the revenue share in the liquid biopsy for cancer diagnostics market in 2022. This high adoption rate within the country can be attributed to its elevated prevalence of cancer cases.

Moreover, patients may face substantial costs associated with cancer diagnosis and treatment, even with medical insurance coverage. The inclusion of liquid biopsy tests in insurance and reimbursement initiatives provided by the US government serves as an additional incentive for their adoption among end users. As an illustration, InVisionFirst®, a Liquid Biopsy for Lung Cancer Patients, falls under the coverage of CMS National Coverage Policy. Consequently, these factors are anticipated to propel the market for liquid biopsy in cancer diagnostics in the United States.

To know more about why North America is leading the market growth in the liquid biopsy in cancer diagnostics market, get a snapshot of the Liquid Biopsy in Cancer Diagnostics Market Outlook 

Liquid Biopsy in Cancer Diagnostics Market Dynamics

The rising prevalence of cancer and the increasing adoption of liquid biopsy in cancer diagnostics are significant factors propelling the growth of liquid biopsy in cancer diagnostics market. The heightened demand for liquid biopsy is primarily driven by the surge in cancer cases. Additionally, the growing emphasis on precision medicine in cancer treatment contributes substantially to the escalating interest in liquid biopsy for diagnostic purposes. Precision medicine, characterized by tailoring treatment plans based on the specific biological characteristics of tumors, represents a novel approach in cancer care. The applications of precision medicine extend across various clinical aspects, including screening, diagnosis, prognosis, predicting treatment responses and resistance, early detection of recurrence/metastasis, and the biological stratification of cancer. Liquid biopsies emerge as a promising avenue for personalized medicine, offering the advantage of multiple non-invasive global snapshots of both primary and metastatic tumors.

The widespread acceptance and focus of physicians on tailoring treatments to individual health conditions have led to increased attention to personalized medicine. Liquid biopsy, a crucial element in crafting customized treatments, plays a significant role in this regard. By offering real-time information about the tumor profile, it guides decisions on subsequent treatment steps. Market players are recognizing the potential of liquid biopsy, as evident from their heightened interest in developing products within this field. As a result, the growing significance of precision medicine, coupled with the advantages of liquid biopsy, is expected to contribute to the expansion of liquid biopsy within the cancer diagnostics market in the forecast period.

Nevertheless, the potential for inaccurate outcomes arising from procedural constraints and the absence of standardized procedures could pose significant challenges to the expansion of the liquid biopsy market in cancer diagnostics.

Get a sneak peek at the liquid biopsy in cancer diagnostics market dynamics @ Liquid Biopsy in Cancer Diagnostics Market Dynamics Analysis

Liquid Biopsy in Cancer Diagnostics Market Assessment

• Liquid Biopsy in Cancer Diagnostics Market Segmentation
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Type: Product Type [Instruments and Reagents & Kits] and Services), Sample Type (Blood, Urine, and Saliva), Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others), Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, and Others)
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Technique: Polymerase Chain Reaction and Next Generation Sequencing
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By End User: Hospitals, Diagnostic Centers, and Others
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Which MedTech key players in the liquid biopsy in cancer diagnostics market are set to emerge as the trendsetter explore @ Liquid Biopsy in Cancer Diagnostics Companies 

Table of Contents 

Interested in knowing the liquid biopsy in cancer diagnostics market by 2028? Click to get a snapshot of the Liquid Biopsy in Cancer Diagnostics Market Trends

Related Reports

Liquid Biopsy for Cancer Diagnostics Competitive Landscape

Liquid Biopsy for Cancer Diagnostics Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Liquid Biopsy in Cancer Diagnostics companies, including Guardant Health, Roche, Neo Genomics, Qiagen, Archer DX, Bio-Techne, Resolution Bioscience, Personal Genome Diagnostics, Helio Health, Lucence Diagnostics, Foundation Medicine Inc, Biocept, Sysmex Ionostics Inc, Veridex LLC (Janssen Diagnostics), Biodesix, Pathway Genomics, Exact Sciences, Angle Plc, GRAIL Inc., NuProbe, Onco Cell MDx Inc, Merck, AmoyDx, among others.

Biopsy Devices Market

Biopsy Devices Market Insight, Competitive Landscape, and Market Forecast – 2028 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biopsy devices companies, including Boston Scientific Corporation, Cardinal Health, Medtronic, BD, Cook, Devicor Medical Products Inc, B. Braun Melsungen AG, ARGON MEDICAL, OLYMPUS CORPORATION, FUJIFILM, INRAD Inc, Hologic Inc, C. R. Bard, Dr. Japan Co Ltd, Limaca-medical, Owlstone Medical Ltd, Zamar Care, KOELIS, ST. STONE MEDICAL DEVICES PVT LTD, Iscon Surgicals Ltd, among others.

Cancer Therapy Market

Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2028 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, among others.

Intratumoral Cancer Therapies Market

Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key intratumoral cancer therapies companies, including Daiichi Sankyo, Amgen, Idera Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Us
Shruti Thakur
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/medical-devices

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg